Type of Specimen	Pathogen	Antibacterial agents
Blood	Staphylococcus aureus	Methicillin*
		Vancomycin
		Clindamycin
Blood	Enterococcus spp.	Ampicillin
		Vancomycin
		Teicoplanin
		Linezolid
		Daptomycin
Blood	Streptococcus pneumoniae	Penicillin G
		Oxacillin
		Co-trimoxazole
		Ceftriaxone
		Cefotaxime
		Erythromycin
		Clindamycin
		Levofloxacin
Blood	Salmonella spp.	Ciprofloxacin
	11	Levofloxacin
		Ceftriaxone
		Cefotaxime
		Ceftazidime
		Imipenem
		Meropenem
		Ertapenem
		Doripenem
Blood	Escherichia coli	Gentamicin
		Amikacin
		Co-trimoxazole
		Ampicillin
		Ciprofloxacin
		Levofloxacin
		Cefpodoxime
		Ceftriaxone
		Cefotaxime
		Ceftazidime
		Cefepime
		Imipenem
		Meropenem
		Ertapenem
		Doripenem
		Colistin
Blood	Klebsiella pneumoniae	Gentamicin
		Amikacin
		Co-trimoxazole
		Ciprofloxacin
		Levofloxacin
		Cefpodoxime
		Ceftriaxone
		Cefotaxime

		Ceftazidime
		Cefepime
		Imipenem
		Meropenem
		Ertapenem
		Doripenem
		Colistin
Blood	Pseudomonas aeruginosa	Ceftazidime
		Ciprofloxacin
		Piperacillin/tazobactam
		Gentamicin
		Amikacin
		Imipenem
		Meropenem
		Doripenem
		Colistin
Blood	Acinetobacter baumannii	Tigecycline
21004		Minocycline
		Gentamicin
		Amikacin
		Imipenem
		Meropenem
		Doripenem
		Colistin

^{*}Oxacillin or cefoxitin may be used as a proxy if methicillin is not tested.

Supplementary Table 2: The list of participating hospitals.

Hospital	City	Country	Availability of AST result data*	Availability of negative culture data	Availability of hospital admission date data	Availability of outcome data**	Sections of AMR report that are available	Website
Angkor Hospital for Children	Siem Reap	Cambodia	Yes	Yes	Yes	Yes	Section 1, 2, 3, 4, 5 and 6	https://doi.org/10.6084/m9.figshare. 12000225.v1
Mahosot Hospital	Vientiane	Lao PDR	Yes	No	No	No	Section 1 and 2	https://doi.org/10.6084/m9.figshare. 12000222.v1
North Okkalapa General and Teaching Hospital	Yangon	Myanmar	Yes	Yes	Yes	Yes	Section 1, 2, 3, 4, 5 and 6	https://doi.org/10.6084/m9.figshare. 12000237.v1
Patan Hospital	Kathmandu	Nepal	Yes	No	No	No	Section 1 and 2	https://doi.org/10.6084/m9.figshare. 12000231.v1
Sunpasitthiprasong Hospital	Ubon Ratchathani	Thailand	Yes	Yes	Yes	Yes	Section 1, 2, 3, 4, 5 and 6	https://doi.org/10.6084/m9.figshare. 12000240.v1
St Thomas' Hospital	London	the United Kingdom	Yes	No	Yes	Yes	Section 1, 2, 3 and 6	https://doi.org/10.6084/m9.figshare. 12000249.v1
Hospital for Tropical Diseases	Ho Chi Minh City	Vietnam	Yes	Yes	No	No	Section 1, 2 and 4	https://doi.org/10.6084/m9.figshare. 12000252.v1

Footnote of Supplementary Table 2. *Antimicrobial susceptibility testing (AST) data on interpretative categories of susceptible, intermediate, and resistant. **In-hospital discharge outcome.

12 13	Supplementary Text 1: The method based on the recommendation of the	ods to estimate prevalence and incidence rates were e WHO GLASS.
14 15 16	Proportion of AMR pathogen:	
	Proportion of patients with positive blood cultures who have resistant strains (%, modified from WHO GLASS ¹¹)	Number of patients with blood culture positive for resistant strains of bacterial species under surveillance (per pathogen per specimen per survey period) Total number of patients with blood culture positive for bacterial species under surveillance (per pathogen per specimen per survey period)
17 18		
19 20	Proportion of AMR pathogen stra	atified by origin of infection:
	Proportion of patients with positive blood culture who have resistant strains per type of origin of infection (%, modified from WHO GLASS ¹¹)	Number of patients with blood culture positive for resistant strains of bacterial species under surveillance (per pathogen per specimen per survey period per origin of infection) Total number of patients with blood culture positive for bacterial species under surveillance (per pathogen per specimen per survey period per origin of infection)
21222324	Incidence of AMR pathogen:	
2425	Frequency of patients with blood culture positive for pathogen (per 100,000 tested patients, modified from WHO GLASS ¹¹)	Number of patients with blood culture positive for bacterial species in the population tested during reporting period * 100,000 (per pathogen per specimen per survey period) Total number of patients with blood culture performed during the reporting period
26	Frequency of patients with blood culture positive for resistant strains (per 100,000 tested patients, modified from WHO GLASS ¹¹)	Number of patients with blood culture positive for resistant strains of bacterial species under surveillance during reporting period * 100,000 (per pathogen per specimen per survey period) Total number of patients with blood culture performed during the reporting period
27 28 29 30 31 32		daring the reporting period

33 34	Incidence of AMR pathogen str	atifi	ed by origin of infection:
	Frequency of patients with blood culture positive for pathogen (per 100,000 tested patients, modified from WHO GLASS ¹¹)	=	Number of patients with blood culture positive for bacterial species in the population tested during reporting period * 100,000 (per pathogen per specimen per survey period per origin of infection) Total number of patients with the first blood culture performed within the first two calendar days of admissions during the reporting period
35 36			
50	Frequency of patients with blood culture positive for resistant strains (per 100,000 tested patients, modified from WHO GLASS ¹¹)	= _	Number of patients with blood culture positive for resistant strains of bacterial species under surveillance during reporting period * 100,000 (per pathogen per specimen per survey period per origin of infection) Total number of patients with the first blood culture performed after the first two calendar days of admission during the reporting period
37			during the reporting period
38			
39			

Supplementary Text 2: Simulating hypothetical data sets.

40

41

42

43

44 45

46

47

48 49

50

51 52


53

54

55


We generated a hypothetical data set for users to test AMASS and to visualize the data required for the application. Two hypothetical (microbiology data.xlsx and hospital admission data.xlsx) were generated using the summary statistics in the AMR surveillance report from Sunpasitthiprasong Hospital in 2015.³² The key variables generated were admission date, discharge date, gender, age (in year), in-hospital discharge outcome, specimen date, specimen type, organism isolated, and antibiogram results. The admission date was sampled from a uniform distribution ranged between 1st January 2016 and 31st December 2016. For bloodstream infections of community-origin, we assumed that the first blood specimen culture positive for the pathogen was collect on the first calendar day of hospitalization. For bloodstream infections of hospital-origin, we assumed that the first blood specimen culture positive for the pathogen was collected on the fourth day of hospitalization. The data was generated using STATA, version 15.1 (StataCorp LP, College station, Texas, USA).


Supplementary Figure 1. An overview on the flow of data processing and analyses performed by AMASS.





*In cases when data on negative blood culture are available


Supplementary Figure 2: How to export data from WHONET 5.6 (2019) in an Excel format that can be used by AMASS. The process helps users with raw disk diffusion zone diameter/MIC values to convert to antimicrobial susceptibility test interpretive categories (susceptible, intermediate, resistant). Data analysis menu (A, C, E, G and I) brings users to separated windows (B, D, F and H), which contains various functions to process the data.























69 70

71

72

73

Footnote of Supplementary Figure 2. The WHONET users may follow the steps below to combine several data files into one, and to standardardise the format to export in Excel format for AMASS. Please note that we have created a data dictionary that is downloadable from www.amass.website for the WHONET users.

- 74 1) Select "Data analysis" under the "Data analysis" tab.
- 75 2) Click "Analysis type" button on the "Data analysis" window.
- 76 3) Select "Isolate listing and summary" tab.
- 77 4) Click "1. Listing" option.
- 78 5) Click "OK" to complete and exit the window.
- 79 6) Click "Options" button on the "Data analysis" window.
- 7) Select "Test interpretations" option under "Isolate listing and summary"
- 8) Click "OK" to complete and exit the window.
- 9) Click "Organisms" button on the "Data analysis" window.
- 10) Select ALL by highlighting the list or type "ALL" in the blank space next to "Code".
- 84 11) Click the right arrow to include the whole list.
- 85 12) Click "OK" to complete and exit the window.
- 86 13) Click "Data files" button on the "Data analysis" window.
- 87 14) Select the data set(s) to be exported.
- 88 15) Click the right arrow to include the data set(s) to be exported.
- 89 16) Click "OK" to complete and exit the window.
- 90 17) Choose "Excel" in the drop-down menu of the "Output to:".
- 91 18) Name the file to be exported.
- 92 19) Click "Begin analysis" to export the data.

93	Supplementary Video 1
94	https://youtu.be/T_jvp7xiIs0
95	
96	Supplementary Video 2
97	https://youtu.be/ItNIdazNy_I